Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home European Markets

Eutelsat Shares Surge on Major Airbus Satellite Contract

Robert Sasse by Robert Sasse
January 14, 2026
in European Markets, Industrial, Mergers & Acquisitions, Space
0
Eutelsat Stock
0
SHARES
13
VIEWS
Share on FacebookShare on Twitter

Shares in French satellite operator Eutelsat soared by nearly 10% in a single trading session. The catalyst was a significant expansion of its partnership with Airbus, securing an order for an additional 340 satellites destined for the OneWeb constellation. This move solidifies the company’s position as Europe’s primary contender against SpaceX’s Starlink in the low-Earth orbit (LEO) broadband arena.

Strategic Expansion and Financial Backing

The new agreement with Airbus Defence and Space, to be executed at the Toulouse facility, brings Eutelsat’s total commitment to 440 next-generation satellites. This figure includes an initial batch of 100 units ordered in December 2024. The total investment for this fleet is projected to reach between €2.0 and €2.2 billion, with expenditures spread through 2029. Initial deliveries are scheduled to commence by the end of 2026.

This substantial procurement is strategically timed to replace Eutelsat’s first-generation OneWeb satellites, which are expected to reach the end of their operational lifespan between 2027 and 2028. A key enhancement for the new fleet involves upgraded digital payloads from technology firm Ramon.Space, which are confirmed for at least 70 of the first 100 satellites. These improvements are designed to facilitate superior connectivity with Eutelsat’s existing geostationary satellites and the forthcoming European Union IRIS² infrastructure project.

Market Reaction and Share Performance

The market responded enthusiastically to the news. Eutelsat’s stock price jumped from approximately €1.92 to over €2.10, marking a gain of 9.6%. Trading volume exceeded 4 million shares, significantly above the daily average of 2.1 million, underscoring heightened investor interest. Despite this positive movement, the share price remains substantially below its peak of over €9.00 in early 2025, a level depressed by subsequent capital increases.

Should investors sell immediately? Or is it worth buying Eutelsat?

Government Support Underpins Ambitious Plans

The financing for this ambitious expansion is already secured. Eutelsat bolstered its balance sheet through two major capital raises in late 2025. The company first gathered €828 million in November from a consortium of anchor investors, including the French and British governments, Indian conglomerate Bharti, shipping group CMA CGM, and several French insurers. This was followed by a further capital increase of €670 million in December. The French state now holds a stake of up to 30%, reflecting Eutelsat’s status as a strategic asset for European space sovereignty.

Key Project Details:
* Total Satellite Order: 440 units
* Total Investment Range: €2.0 – €2.2 billion (2024-2029)
* First Deliveries: Late 2026
* Projected LEO Segment Growth: 80% revenue increase in 2025

With a planned constellation of over 600 satellites across 12 orbital planes, Eutelsat operates the sole fully functional European LEO network alongside Starlink. The company’s focus remains on business-to-business segments, including maritime and in-flight connectivity, services for government agencies, and providing broadband to underserved regions. Eutelsat currently commands a market capitalization of around €2.5 billion, with its shares trading at a price-to-book ratio of 0.87.

Ad

Eutelsat Stock: Buy or Sell?! New Eutelsat Analysis from February 8 delivers the answer:

The latest Eutelsat figures speak for themselves: Urgent action needed for Eutelsat investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Eutelsat: Buy or sell? Read more here...

Tags: Eutelsat
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Rock Tech Lithium Stock
Analysis

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Vigil Neuroscience Stock
Healthcare

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Graftech Stock
Commodities

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026
Next Post
Aventis Energy Stock

Aventis Energy Nears Critical Drilling Milestone at Corvo Uranium Project

Marvell Technology Stock

Diverging Paths: Institutional Investors Split on Marvell Technology's AI Prospects

Voestalpine Stock

Voestalpine's Strategic Digital Investment Signals Long-Term Strength

Recommended

FCBC stock news

Impax Asset Management Group plc Reduces Stake in Snap Inc. as Insiders Sell Off Shares

2 years ago
The Trade Desk Stock

The Trade Desk: A Market Conundrum of Conflicting Signals

3 months ago
Intel Stock

US Government Holds Massive Intel Share Position, Creating Market Uncertainty

5 months ago
Nuvalent Stock

Nuvalent Shares Surge on Promising Clinical Trial Results

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

DroneShield Shares Face Headwinds Despite Record Performance

Rock Tech Lithium: Investors Await the Final Go-Ahead

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Trending

KemPharm Stock
Analysis

Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

by Kennethcix
February 8, 2026
0

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations...

Oak Valley Stock

Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit

February 8, 2026
SuRo Capital Stock

SuRo Capital Sharpens Focus on AI Infrastructure Investments

February 8, 2026
Chicago Atlantic Real Estate Finance Stock

Tax Clarity and Sector Optimism Bolster Outlook for Chicago Atlantic

February 8, 2026
RBB Stock

RBB Bancorp Reports Strong Asset Quality Improvement and Strategic Capital Review

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion
  • Oak Valley Bancorp Surpasses $2 Billion Milestone with Record Annual Profit
  • SuRo Capital Sharpens Focus on AI Infrastructure Investments

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com